Graft versus host disease (GVHD) prophylaxis using postransplant cyclophosphamide (PTCy) preserves T regulatory CD4+lymphocytes (Tregs) in unmanipulated haploidentical transplantation (Haplo-SCT) patients

被引：0
|
作者：
Perez-Corral, A. M. [1 ]
Pascual, C. [1 ]
Gayoso, J. [1 ]
Kwon, M. [1 ]
Champ, D. [1 ]
Balsalobre, P. [1 ]
Munoz, C. [1 ]
Bastos, M. [1 ]
Serrano, D. [1 ]
Anguita, J. [1 ]
Diez-Martin, J. L. [1 ]
机构：
[1] Hosp Gen Gregorio Maranon, Hematol, Madrid, Spain
来源：
BONE MARROW TRANSPLANTATION | 2016年 / 51卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
P248
引用
收藏
页码：S243 / S244
页数：2
相关论文
共 22 条
  • [1] Graft-Versus-Host Disease (GvHD) Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation (haplo-PBSCT) Using Abatacept in Combination with Post-Transplant Cyclophosphamide (PTCy)
    Kaur, Sukhdeep
    Gelman, Simon
    Rowley, Scott
    Baker, Eliana
    Baker, Melissa
    Suh, Hyung C.
    Cho, Christina
    Donato, Michele L.
    BLOOD, 2023, 142
  • [2] POST TRANSPLANT CYCLOPHOSPHAMIDE (CYPT) AS PROPHYLAXIS IN GRAFT DISEASE AGAINST RECEPTOR (EICR) PRESERVES REGULATORY T LYMPHOCYTES CD4+IN PATIENTS WITH HAPLOIDENTIC TRANSPLANTATION
    Virginia, Pradillo
    Ana Maria, Perez-Corral
    Nieves, Dorado
    Cristina, Pascual
    Jorge, Gayoso
    Mi, Kwon
    Diana, Champ
    Pascual, Balsalobre
    Cristina, Munoz
    Mariana, Bastos
    David, Serrano
    Javier, Anguita
    Jose Luis, Diez-Martin
    HAEMATOLOGICA, 2016, 101 : 48 - 48
  • [3] Risk Factors for Graft-Versus-Host Disease (GVHD) in Haploidentical Hematopoietic Cell Transplantation (HCT) Using Post-Transplant Cyclophosphamide (PTCy)
    Rashidi, Armin
    Hamilton, Betty K.
    Wang, Tao
    Hemmer, Michael T.
    Spellman, Stephen R.
    Alousi, Amin M.
    Jagasia, Madan
    Pidala, Joseph A.
    Arora, Mukta
    Im, Annie P.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
  • [4] Post-Transplant Cyclophosphamide (PTCy) Based Graft Versus Host Disease (GVHD) Prophylaxis is Safe and Effective in Elderly Patients over Age 70 Years Undergoing Allogeneic (Allo) Stem Cell Transplantation (SCT)
    Nath, Rajneesh
    Kodali, Murali
    Kamal, Ashan
    Ulrickson, Matthew
    Go, Aileen
    Madan, Sumit
    Heers, Haley
    De Padova, Nicholas
    Miller, Richelle
    Mohammed, Reeshma
    Yasuda, Rachel
    Pebler, Haley
    Zhou, Zheng
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S537 - S538
  • [5] CD45RA+Regulatory T Cells (Tregs) in the Graft is Inversely Related to Donor Age and Impacts Early Alloreactivity and Survival in Younger Patients Undergoing Haploidentical PBSC Transplantation with Post-Transplantation Cyclophosphamide (PTCy)
    Jaiswal, Sarita
    Bhakuni, Prakash
    Bharadwaj, Priyanka
    Joy, Aby
    Chakrabarti, Aditi
    Zaman, Shamsuz
    Chakrabarti, Suparno
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (03) : S83 - S84
  • [6] Myeloid-derived suppressor cell (MDSC) recovery after allogeneic hematopoietic cell transplantation (ALLOHCT) using post-transplant cyclophosphamide (PTCY) as graft-versus-host disease (GVHD) prophylaxis in children
    Oshrine, Benjamin
    Verdugo, Patrick
    Innamarato, Pasquale
    Pilon-Thomas, Shari
    BONE MARROW TRANSPLANTATION, 2019, 54 : 485 - 486
  • [7] Haploidentical peripheral blood stem cell (PBSC) transplantation with combination of CD34 selection and T cell depletion as graft versus host disease (GVHD) prophylaxis in a patient with severe combined immunodeficiency (SCID).
    Hernandez, MPM
    Arrieta, R
    Sastre, A
    Martinez, A
    DeMiguel, PG
    Yuste, VJ
    Luaces, MR
    Lafuente, A
    Mateos, P
    Hernandez, OE
    BLOOD, 1997, 90 (10) : 4420 - 4420
  • [8] Graft-Versus-Host Disease (GVHD) Prophylaxis with Post-Transplant Cyclophosphamide (PTCY) Induces a More Tolerant Immune Response after Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients Previously Exposed to Nivolumab
    Nieto, Juan C.
    Roldan, Elisa
    Jimenez, Isabel
    Fox, Laura
    Carabia, Julia
    Orti, Guillermo
    Puigdefabregas, Lluis
    Gallur, Laura
    Iacoboni, Gloria
    Raheja, Priyanka
    Perez, Ana
    Salamero, Olga
    Palacio, Carlos
    Valcarcel, David
    Crespo, Marta
    Bosch, Francesc
    Barba, Pere
    BLOOD, 2018, 132
  • [9] Haploidentical T-cell replete hematopoietic transplantation conditioned with thiotepa-busulfan-fludarabine (TBF) followed by high-dose cyclophosphamide and tacrolimus as graft versus host disease prophylaxis in 33 patients with myeloid disease
    Esquirol, A.
    Pascual, M. J.
    Ortiz, M.
    Pinana, J. L.
    Ferra, C.
    Irene, G.
    Vilades, I.
    Brunet, S.
    Martino, R.
    Sierra, J.
    BONE MARROW TRANSPLANTATION, 2016, 51 : S146 - S147
  • [10] Direct Integration of Anti-CD19 Chimeric-Antigen-Receptor (CAR) T Cells Early after Post-Transplantation Cyclophosphamide (PTCy) in Murine MHC-Haploidentical Hematopoietic Cell Transplantation (HCT) Exerts Anti-Tumor Effects without Causing Graft-Versus-Host Disease (GVHD)
    Patterson, Michael T.
    Mendu, Suresh K.
    Eckhaus, Michael A.
    Fletcher, Rochelle E.
    Nunes, Natalia S.
    Ishii, Kazusa
    Qin, Haiying
    Fry, Terry J.
    Kanakry, Christopher G.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S170 - S171
123